PMID- 20956117
OWN - NLM
STAT- MEDLINE
DCOM- 20110207
LR  - 20120110
IS  - 1600-0617 (Electronic)
IS  - 0905-9180 (Linking)
VI  - 18
IP  - 111
DP  - 2009 Mar
TI  - High-altitude pulmonary hypertension.
PG  - 13-7
LID - 10.1183/09059180.00011104 [doi]
AB  - High-altitude pulmonary hypertension (HAPH) is a specific disease affecting 
      populations that live at high elevations. The prevalence of HAPH among those 
      residing at high altitudes needs to be further defined. Whereas reduction in 
      nitric oxide production may be one mechanism for the development of HAPH, the 
      roles of endothelin-1 and prostaglandin I(2) pathways in the pathogenesis of HAPH 
      deserve further study. Although some studies have suggested that genetic factors 
      contribute to the pathogenesis of HAPH, data published to date are insufficient 
      for the identification of a significant number of gene polymorphims in HAPH. The 
      clinical presentation of HAPH is nonspecific. Exertional dyspnoea is the most 
      common symptom and signs related to right heart failure are common in late stages 
      of HAPH. Echocardiography is the most useful screening tool and right heart 
      catheterisation is the gold standard for the diagnosis of HAPH. The ideal 
      management for HAPH is migration to lower altitudes. Phosphodiesterase 5 is an 
      attractive drug target for the treatment of HAPH. In addition, acetazolamide is a 
      promising therapeutic agent for high-altitude pulmonary hypertension. To date, no 
      evidence has confirmed whether endothelin-receptor antagonists have efficacy in 
      the treatment of high-altitude pulmonary hypertension.
FAU - Xu, X-Q
AU  - Xu XQ
AD  - Dept of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University, 
      China.
FAU - Jing, Z-C
AU  - Jing ZC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur Respir Rev
JT  - European respiratory review : an official journal of the European Respiratory 
      Society
JID - 9111391
SB  - IM
MH  - *Altitude
MH  - Humans
MH  - Hypertension, Pulmonary/*etiology/therapy
EDAT- 2009/03/01 00:00
MHDA- 2011/02/08 06:00
CRDT- 2010/10/20 06:00
PHST- 2010/10/20 06:00 [entrez]
PHST- 2009/03/01 00:00 [pubmed]
PHST- 2011/02/08 06:00 [medline]
AID - 18/111/13 [pii]
AID - 10.1183/09059180.00011104 [doi]
PST - ppublish
SO  - Eur Respir Rev. 2009 Mar;18(111):13-7. doi: 10.1183/09059180.00011104.